Cargando…

Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy

BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxalipla...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Hao, Ying, Zhu, Lihua, Li, Sen, Zuo, Yanjiao, Zhang, Yuxin, Song, Hongjiang, Xue, Yingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558583/
https://www.ncbi.nlm.nih.gov/pubmed/28860808
http://dx.doi.org/10.2147/OTT.S140118
_version_ 1783257409744011264
author Chen, Li
Hao, Ying
Zhu, Lihua
Li, Sen
Zuo, Yanjiao
Zhang, Yuxin
Song, Hongjiang
Xue, Yingwei
author_facet Chen, Li
Hao, Ying
Zhu, Lihua
Li, Sen
Zuo, Yanjiao
Zhang, Yuxin
Song, Hongjiang
Xue, Yingwei
author_sort Chen, Li
collection PubMed
description BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) neoadjuvant chemotherapy regimen. METHODS: The data from Harbin Medical University Cancer Hospital from August 2008 to September 2015 were retrospectively collected. Ninety-one patients with advanced gastric cancer treated with neoadjuvant chemotherapy were included. The blood samples were collected before neoadjuvant chemotherapy. The MLR was divided into two groups: Low-MLR <0.27 group and high-MLR ≥0.27 group. Survival curves were performed using the Kaplan–Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression model were evaluated to determine independent prognostic factors. RESULTS: The univariate analysis showed that median disease free survival (DFS) and overall survival (OS) for all patients were better in low-MLR value group than high-MLR value group (median DFS 26.80 and 23.73 months, P=0.653, respectively; median OS 27.93 and 26.87 months, P=0.807, respectively). Multivariate analysis showed that MLR level was not an independent prognostic factor of DFS and OS. Nevertheless, median DFS and OS for all patients were better for patients with low monocyte values compared to those with high monocyte values (median DFS 30.23 and 21.03 months, P=0.645, respectively; median OS 37.97 and 25.83 months, P=0.509, respectively); in patients with high lymphocyte values compared with low lymphocyte values median DFS was 26.87 and 21.03 months, (P=0.624) respectively; median OS was 27.93 and 26.37 months, (P=0.584) respectively. However, the patients with low level MLR had better 5-year DFS and OS rates. CONCLUSION: MLR may be used as a convenient and cheap prognostic marker in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy with SOX or XELOX. Low level MLR as a prognostic marker may help doctors in terms of efficient measures to treat gastric cancer.
format Online
Article
Text
id pubmed-5558583
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55585832017-08-31 Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy Chen, Li Hao, Ying Zhu, Lihua Li, Sen Zuo, Yanjiao Zhang, Yuxin Song, Hongjiang Xue, Yingwei Onco Targets Ther Original Research BACKGROUND: Currently, precise predictors in gastric cancer patients undergoing neoadjuvant chemotherapy are lacking. The study aims to investigate the prognostic value of the monocyte to lymphocyte ratio (MLR) in patients with advanced gastric cancer receiving S-1 plus oxaliplatin (SOX) or oxaliplatin and capecitabine (XELOX) neoadjuvant chemotherapy regimen. METHODS: The data from Harbin Medical University Cancer Hospital from August 2008 to September 2015 were retrospectively collected. Ninety-one patients with advanced gastric cancer treated with neoadjuvant chemotherapy were included. The blood samples were collected before neoadjuvant chemotherapy. The MLR was divided into two groups: Low-MLR <0.27 group and high-MLR ≥0.27 group. Survival curves were performed using the Kaplan–Meier method and compared using the log-rank test. Univariate and multivariate Cox proportional hazards regression model were evaluated to determine independent prognostic factors. RESULTS: The univariate analysis showed that median disease free survival (DFS) and overall survival (OS) for all patients were better in low-MLR value group than high-MLR value group (median DFS 26.80 and 23.73 months, P=0.653, respectively; median OS 27.93 and 26.87 months, P=0.807, respectively). Multivariate analysis showed that MLR level was not an independent prognostic factor of DFS and OS. Nevertheless, median DFS and OS for all patients were better for patients with low monocyte values compared to those with high monocyte values (median DFS 30.23 and 21.03 months, P=0.645, respectively; median OS 37.97 and 25.83 months, P=0.509, respectively); in patients with high lymphocyte values compared with low lymphocyte values median DFS was 26.87 and 21.03 months, (P=0.624) respectively; median OS was 27.93 and 26.37 months, (P=0.584) respectively. However, the patients with low level MLR had better 5-year DFS and OS rates. CONCLUSION: MLR may be used as a convenient and cheap prognostic marker in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy with SOX or XELOX. Low level MLR as a prognostic marker may help doctors in terms of efficient measures to treat gastric cancer. Dove Medical Press 2017-08-10 /pmc/articles/PMC5558583/ /pubmed/28860808 http://dx.doi.org/10.2147/OTT.S140118 Text en © 2017 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Chen, Li
Hao, Ying
Zhu, Lihua
Li, Sen
Zuo, Yanjiao
Zhang, Yuxin
Song, Hongjiang
Xue, Yingwei
Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title_full Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title_fullStr Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title_full_unstemmed Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title_short Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
title_sort monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558583/
https://www.ncbi.nlm.nih.gov/pubmed/28860808
http://dx.doi.org/10.2147/OTT.S140118
work_keys_str_mv AT chenli monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT haoying monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT zhulihua monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT lisen monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT zuoyanjiao monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT zhangyuxin monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT songhongjiang monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy
AT xueyingwei monocytetolymphocyteratiopredictssurvivalinpatientswithadvancedgastriccancerundergoingneoadjuvantchemotherapy